





CIGNA PHARMACY MANAGEMENT

CLINICAL UPDATE - NOVEMBER 2020

Today, 60% of all medication costs are attributed to specialty medications.¹ With a rapidly growing number of FDA-approved products, **integrated management of specialty conditions across benefits** will be critical to optimizing clinical outcomes and controlling costs.

2021 Specialty Drug and Biologic Pipeline				
<div><div> 100+</div><div>Drugs expected to receive FDA approval in 2021*</div></div> <div><div></div><div>Approximately two thirds are specialty drugs*</div></div> <div><div></div><div>25% classified as orphan drugs (treating rare conditions)*</div></div> <div><div></div><div>40% expected to be covered under the medical benefit*</div></div>	<div><div>CONDITION</div><div>Alzheimer's disease First therapy to help reduce clinical decline for early stage Alzheimer's disease.</div></div>	<div><div>DRUG</div><div>aducanumab (intravenous infusion)</div></div>	<div><div>ESTIMATED COST</div><div>\$50,000-\$100,000/yr; administered every 4 weeks</div></div>	<div><div>ANTICIPATED FDA DECISION</div><div>March 2021 FDA will consider that their advisory panel recently recommended against approval</div></div>
	<div><div>Eczema</div><div>Targets underlying inflammatory process of this chronic skin disease.</div></div>	<div><div>tralokinumab (subcutaneous injection)</div></div>	<div><div>\$40,000/yr; administered every 2 weeks</div></div>	<div><div>April 2021</div></div>
	<div><div>Oncology</div><div>Oncology treatment continues to become more specific and highly targeted with these CAR-T therapies.² Additional gene therapies for prostate and bladder cancers could receive approval in 2021.</div></div>	<div><div>abrocitinib (oral)</div></div>	<div><div>\$40,000/yr; administered once daily</div></div>	<div><div>April 2021</div></div>
		<div><div>Large B-cell lymphoma (lisocabtagene - Breyanzi) lisocabtagene (intravenous infusion)</div></div>	<div><div>\$373,000/treatment; 1-2 infusions for treatment</div></div>	<div><div>November 2020</div></div>
		<div><div>Multiple myeloma idecabtagene (intravenous infusion)</div></div>	<div><div>\$475,000/treatment; 1 infusion for treatment</div></div>	<div><div>March 2021</div></div>
	<div><div>Multiple myeloma ciltacabtagene (intravenous infusion)</div></div>	<div><div>\$475,000/treatment; 1 infusion for treatment</div></div>	<div><div>2021</div></div>	<div><div>February 2021</div></div>
		<div><div>Duchenne muscular dystrophy (DMD) Rare condition affecting ~10,000 young males in the U.S. An additional gene therapy may receive approval late 2021 or early 2022 to be used more broadly in the DMD population.</div></div>	<div><div>casimersen (intravenous infusion)</div></div>	
	<div><div>Hemophilia B First gene therapy for hemophilia B, a hereditary bleeding disorder that affects approximately 4,100 individuals in the U.S. Gene therapies for the more common hemophilia A are not expected until 2022.</div></div>	<div><div>etranacogene (intravenous infusion)</div></div>	<div><div>\$1.5 million/treatment; 1 infusion for treatment</div></div>	<div><div>2021</div></div>
	<div><div>Biosimilars</div><div>- Additional biosimilars for Rituxan, Avastin, Neupogen, and Neulasta may receive approval late 2020/2021 and will join others currently on the market.</div></div>			

* Cigna internal analysis, 2020



With integrated medical, pharmacy, and behavioral, we manage specialty drugs across all benefits. We use advanced analytics, real-time data, and a whole person view to provide proactive solutions that support the body and mind, driving better health and financial outcomes.

Controlling Costs

Whole Person Support

Through case management, prior authorization, and medical director reviews, our **Site of Care solution helps ensure treatment in the lowest cost setting ~ \$87K savings per intervention per year.** ³

The option of **buy and bill** through the health care provider’s office often provides significant purchasing discounts on the drug.

- If an alternative setting is required, we aggressively negotiate with outpatient facilities or hospitals to lower the drug cost. Or, we may seek out 340b pricing if eligible or fulfill through Accredo®, our Cigna specialty pharmacy.
- If home health care is the best option, we can leverage the vast clinical resources on staff with Accredo to support our customers.

With our connected benefits, we are able to manage drug costs for those covered under the medical benefit through **aggressive doctor fee schedules**, consistently achieving discounts of Average Wholesale Price (AWP) **minus 30% or more.** ⁴

We are able to remove manufacturer copay assistance impact from customer deductibles/maximums with **Out of Pocket Adjuster.** ⁵

We maximize copay assistance amounts from manufacturers for certain specialty medications with **SaveOnSP.** ⁵


We prefer biosimilars over original brand 80+% of the time to help reduce the costs of specialty drugs, improve adherence and improve outcomes.

With connected benefits and consistent coverage policies across both medical and pharmacy benefits, we are able to provide our customers with personalized, proactive support to help them achieve their best health outcomes from their **very first fill at Accredo.**

Through our condition-specific **Accredo Therapeutic Resource Centers® (TRC)**, we provide one-on-one, personalized care to those taking specialty medications for conditions like Multiple Sclerosis, Rheumatoid Arthritis, bleeding disorders, rare conditions, and oncology.

Our teams are comprised of highly trained pharmacists, nurses, nutritionists and social workers, who have extensive experience in specific disease states and medications.

 **500+**
condition-focused Accredo
pharmacists ⁶

 **99.1%**
access to specialty drugs
through Accredo ⁷

 **600+**
dedicated Accredo home
infusion nurses ⁶

 **850**
million dollars in
coordinated financial
assistance for 2019 ⁸



1. Cigna internal analysis of 2019 commercial claim data. 2. Chimeric antigen receptor T-cell (CAR-T) therapies. 3. Cigna claims analysis 2018. 4. Average of all drugs on national medical SRx fee schedules. Based on Cigna 2017 contracting data. 5. Product availability varies by state and plan design. 6. Accredo operations data, 2019. 7. Accredo operations data, 2019. Subject to change. 8. 2019 analysis based on Express Scripts adjudicated claims volume for commercial and health plan payers for limited distribution, exclusive distribution, and open access specialty drugs.

Product availability may vary by location and plan type and is subject to change. All group health insurance policies and health benefit plans contain exclusions and limitations. For costs and details of coverage, contact a Cigna representative.

Health benefit plans vary, but in general to be eligible for coverage a drug must be approved by the Food and Drug Administration (FDA), prescribed by a health care professional, purchased from a licensed pharmacy and medically necessary. All Cigna products and services are provided exclusively by or through operating subsidiaries of Cigna Corporation, including Cigna Health and Life Insurance Company (CHLIC), Express Scripts, Inc., Accredo Health Group, Inc., and HMO or service company subsidiaries of Cigna Health Corporation. Policy forms: OK - HP-APP-1 et al., OR - HP-POL38 02-13, TN - HP-POL43/HC-CER1V1 et al. (CHLIC).